Rx License-Rx

TAB-3890

Topical Sodium Nitrate Ointment for Sickle Cell Disease

Chronic leg ulcers are a debilitating vasculopathic complication for some patients with sickle cell disease (SCD). Prevalence of leg ulcers varies based on age and geographic location; about 5-10% of all SCD patients may suffer leg ulcers. These leg ulcers are painful, result in infections, hospitalization, disability, and negatively impact the patient’s social and psychological wellbeing on an ongoing basis. Until recently, patients with SCD only had one drug treatment option: hydroxyurea, which was approved by the Food and Drug Administration (FDA) in 1998 in adults and in 2017, in children age 2 and older. However, there are no FDA-approved treatments specifically to treat SCD ulcers. The ulcer may take months or even years to heal. Opioid drugs are often administered to relieve intense pain symptoms, but the opioids do not treat the underlying wound conditions and carry addiction risks with chronic use. Thus, there is an unmet...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Cardiometabolic

Indication: Sickle cell disease

Modality: Drug Delivery

Focus tags: Cardiometabolic, Neurology, Rare Disease, Infectious Disease

Technology tags: Drug Delivery

Mechanism:

Development stage: Clinical

Patent status: Issued; Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Cardiometabolic. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be clinical and is associated with National Institutes of Health. The practical first use case is Sickle cell disease. Public description: Chronic leg ulcers are a debilitating vasculopathic complication for some patients with sickle cell disease (SCD). Prevalence of leg ulcers varies based on age and geographic location; about 5-10% of all SCD patients may suffer leg ulcers.

What is exciting

More mature than a typical academic invention: Prior human, regulatory, or deployment evidence can shorten diligence and make strategic buyers more comfortable.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Negatives / diligence concerns

Clinical context matters: A clinical-stage label is only useful if the trial design, population, endpoints, safety signal, and follow-on plan are strong.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Cardiometabolic wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Eli Lilly — Neurodegeneration leadership and biomarker-driven trial infrastructure. Biogen — CNS portfolio gap-filling and translational neurology focus. Roche — CNS diagnostics, biomarkers, and global development scale.

Development Strategy to Increase PoS

First indication: Sickle cell disease

Study design: Mechanism-first biomarker study before any broad symptomatic endpoint trial.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.